Prevalence of anti hepatitis B surface antibody among children in Ahvaz, Iran, five years after vaccination

Jundishapur Journal of Microbiology

Volumn 4, Issue 1, 2011, Pages 49-54

  Shamsizadeh, Ahmad ^a   Makvandi, Manoochehr ^a   Shoshtari, Gholamali ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anti HBs; Children; Iran; Vaccination

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS B; HUMAN; IRAN; MALE; PRESCHOOL CHILD; SEROPREVALENCE; SEX DIFFERENCE; VACCINATION;

HEPATITIS B VIRUS;

EID: 78649742489     PISSN: 20083645     EISSN: 20084161     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Su FH, Chen JP, Cheng SH, Sung KY, Jeng JJ, Chu FY. Waning off effect of serum hepatitis B surface antibody amongst Taiwanese university students. 18 years post implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat. 2008; 15(1): 14-9.
2. Su FH, Cheng SH, Li CY, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007; 25(47): 8085-90.
3. Giambi C, Bella A, Barale A, et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis. 2008; 8: 100.
4. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Book H, Leyssen M, Jacquet JM. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine. 2010; 28(3): 730-6.
5. Bialek SR, Bower WA, Novak R, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15 year follow up study. Pediatr Infect Dis J. 2008; 27(10): 881-5.
6. McMahon BJ, Dentinger CM, Bruden D, et al. antibody levels and protection after hepatitis B vaccine: results of a 22 year follow up study and response to a booster dose. J Infect Dis. 2009; 200(9): 1390-6.
7. Lu JJ, Cheng CC, Chou SM, Hor CB, Yang YC, Wang HL. Hepatitis B immunity in adolescents and necessity for boost vaccination: 23 years after nationwide hepatitis B virus vaccination program in Taiwan. Vaccine. 2009; 27(47): 6613-8.
8. Alfaleh F, Alshebri S, Alansari S, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008; 57(5): 404-9.
9. Gabbuti A, Romano L, Blanc P, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine. 2007; 25 (16): 3129-32.
10. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2006; 18(4): 4-9.
11. Jafarzadeh A, Zarei S, Shokri F. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates. Vaccine. 2008: 26(2): 269-76.
12. Alavian SM, Mansouri S, Abouzari M, Assari S, Bonab MS, Miri SM. Long-term efficacy of hepatitis B vaccination in healthcare workers of Oil Company Hospital, Tehran, Iran (1998-2005). Eur J Gastroenterol Hepatol. 2008; 20(2): 131-4.
13. Sherlock S, Dolley J. Diseases of the liver and biliary system. 10th ed. Oxford, Blackwell Science. 1997; 274-86.
14. Petersen KM, Bulkow LR, McManon BJ, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccination from birth. Pediatr Infect Dis J. 2004; 23(7): 650-5.
15. Wang LY, Lin HH. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine. 2007; 27(41): 7160-7.
16. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003; 187(1): 134-8.
17. Su FH, Chen JD, Cheng SH, Lin CH, Liu YH, Chu FY. Seroprevalence of hepatitis B infection amongst Taiwanese university students 18 years following the commencement of a national hepatitis B vaccination program. J Med Viral. 2007; 79(2): 138-43.
18. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroentrology. 2007; 132(4): 1287-93.
19. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15 year follow up. Ann Intern Med. 2005; 142(5): 333-41.
20. Burgess MA, McIntyre PB, Hellard M, Ruff TA, Lefevre I, Bock HC. Antibody persistence six years after two doses of combined hepatitis A and B vaccine. Vaccine. 2010; 28(10): 2222-6.
21. Kurugol Z, Erensoy S, Aksit S, Egemen A, Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5 year follow up study. Vaccine. 2001; 19(28-29): 3936-9.
22. Jabber SM. Prevalence of anti-hepatitis B and anti hepatitis A antibodies among school aged children in Western Saudi Arabia. Saudi Med J. 2006; 27(10): 1515-22.
23. Hammitt LL, Hennessy TW, Fiore AE, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth. A follow up study at 15 years. Vaccine. 2007; 25(39-40). 6958-64.
24. Yven MF, Lim WC, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow up study of a prospective randomized trial of hepatitis B vaccination without booster doses in children. Clin Gastroenterol Hepatol. 2004; 2(10): 941-5.
25. Zanetti AR, Mariano A, Romano L. Longterm immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet. 2005; 366(9494): 1337-8.
26. Manatvala JE, Van Damme P. hepatitis B vaccine-do we need boosters? J Viral Hepat. 2003; 10(1): 1-6.
27. Lu CY, Chiang BL, Chen PJ, et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after cellular immunization. J Infect Dis. 2008; 19(10): 1419-26.
28. Kao JT, Wang JH, Hang CH, et al. Longterm efficacy of plasma-derived and recombinant hepatitis B vaccination in a rural township of central Taiwan. Vaccine. 2009; 27(12): 1858-62.
29. Chen CC, Yen CH, Wu WY, et al. Epidemiology of hepatitis B virus infection among young adults in Taiwan, China after public vaccination program. Chin Med J. 2007; 120(13): 1155-8.